TQ Quiz | Neurotrophic Keratitis and Biologic Agents for the Eye (Scottsdale 2025) by Events@optometricedu.com | Jan 27, 2025 | 2025 Scottsdale, TQ Courses | 0 comments "*" indicates required fields This field is hidden when viewing the formDate (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent 60 days past date (Hidden) MM slash DD slash YYYY This field is hidden when viewing the formEvent Date Difference (Hidden)1. Which class of drugs are produced using a living system, such as a microorganism, plant cell, or animal cell?* A. Opioid drugs B. Analgesic drugs C. Antiviral drugs D. Biologic drugs 2. The manufacturing process of a biologic drug is closest to ______________?* A. organic chemistry B. genetic engineering C. inorganic chemistry D. analytical chemistry 3. When comparing the size of a chemically synthesized drug to a biologic drug, generally biologics are ___________________________?* A. much smaller the new nanotechnology B. generally slightly smaller C. the same size as chemically synthesized drugs D. larger in size 4. When comparing the complexity of a chemically synthesized drug to a biologic drug, which of the following is true?* A. Biologics are more complex B. Biologics and chemically synthesized drugs are equally complex C. Biologics are slightly less complex D. Biologics are simple molecules 5. Most biologic drugs are given________?* A. orally B. sublingually C. as an injection or infusion D. rectally 6. Which term most closely fits the following definition: “A biologic medical product, also known as a biologic that is highly similar to another already approved biologic medicine or the reference medicine”?* A. Generic medication B. All-purpose biologic C. Copycat biologic D. Biosimilar drug 7. Which biologic drug is indicated for eye care and is the only one administrated as an eye drop?* A. Teprotumumab-trbw (Tepezza) B. Cenegermin –bkbj (Oxervate) C. Tocilizumab (Actemra) D. Adalimumab (Humira) 8. Which biologic drug is indicated for thyroid eye disease?* A. Teprotumumab-trbw (Tepezza) B. Cenegermin–bkbj (Oxervate) C. Tocilizumab (Actemra) D. Adalimumab (Humira) 9. Which biologic drug is indicated for the treatment of neurotrophic keratitis?* A. Teprotumumab-trbw (Tepezza) B. Cenegermin–bkbj (Oxervate) C. Tocilizumab (Actemra) D. Adalimumab (Humira) 10. Which biologic drug has an indication for the treatment of giant cell arteritis (GCA) in adult patients?* A. Teprotumumab-trbw (Tepezza) B. Cenegermin–bkbj (Oxervate) C. Tocilizumab (Actemra) D. Adalimumab (Humira) 11. Which biologic drug is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and children 2 years of age and older?* A. Teprotumumab-trbw (Tepezza) B. Cenegermin–bkbj (Oxervate) C. Tocilizumab (Actemra) D. Adalimumab (Humira) 12. Which of the following ocular biologic drugs is NOT indicated for the treatment of neovascular (wet) age-related macular degeneration?* A. Bevacizumab (Avastin) B. Teprotumumab-trbw (Tepezza) C. Brolucizumab-dbll (Beovu) D. Ranibizumab (Lucentis) 13. Which biologic drug is an injection and is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD), it offers a 3-month dosing schedule in the first year of treat, but when used resulted in an adverse intraocular inflammation events?* A. Bevacizumab (Avastin) B. Ranibizumab (Lucentis) C. Aflibercept (Eylea) D. Brolucizumab-dbll (Beovu) 14. Which biologic drug is the first ophthalmology biosimilar approved by US-FDA? It is indicated to treat wet AMD, Macular Edema following RVO, and myopic CNVM,* A. Bevacizumab (Avastin) B. Ranibizumab (Lucentis) C. Ranibizumab-nuna (Byooviz) D. Aflibercept (Eylea) 15. Which of the following mechanisms most closely describes how Teprotumumab-trbw (Tepezza) works?* A. It binds to IGF-1 receptor and blocks its activation and signaling B. It is an exact copy human nerve growth factor C. It blocks vascular endothelial growth factor D. It binds to TNF and blocks its action in the body 16. Which of the following mechanisms most closely describes how Adalimumab (Humira) works?* A. It binds to IGF-1 receptor and blocks its activation and signaling. B. It is an exact copy human nerve growth factor. C. It blocks vascular endothelial growth factor. D. It binds to TNF and blocks its action in the body. 17. Which of the following mechanisms most closely describes how cenegermin–bkbj (Oxervate) works?* A. It binds to IGF-1 receptor and blocks its activation and signaling B. It is a recombinant form of human nerve growth factor C. It blocks vascular endothelial growth factor D. It binds to TNF and blocks its action in the body 18. Which of the following mechanisms most closely describes how Bevacizumab (Avastin) works?* A. It binds to IGF-1 receptor and blocks its activation and signaling B. It is a recombinant form of human nerve growth factor C. It blocks vascular endothelial growth factor D. It binds to TNF and blocks its action in the body. 19. Baricitinib (Olumiant) and upadacitinib (Rinvoq) are biologic drugs approved to treat moderate to severe rheumatoid arthritis. They are unique because they are taken _________.* A. orally B. sublingually C. as an injection or infusion D. rectally 20. Erenumab-aooe (Aimovig) and fremanezumab-vfrm (Ajovy) are monoclonal antibody biologic drugs that target the calcitonin gene-related peptide receptor for the prevention of ___________?* A. rheumatoid arthritis B. thyroid eye disease C. migraines in adults D. giant cell arteritis in adults Personal InformationName* First Last Email* Phone*OE Tracker #License #Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationPromotional CodeScottsdale 2025 - Neurotrophic Keratitis and Biologic Agents for the Eye*After 90 days, pricing will increase to $30. Price: (Past 90 Days) Scottsdale 2025 - Neurotrophic Keratitis and Biologic Agents for the EyeThis course was presented over 90 days ago. Due to this late submission of TQ, your TQ credit price is $30. Price: Retake Discount Price: Promotional Discount Price: (Past 60 Days) Retake Discount Price: (Past 60 Days) Promotional Discount Price: Credit Card* This field is hidden when viewing the formCourse Information (HIDDEN)This field is hidden when viewing the formCourse Name (HIDDEN)This field is hidden when viewing the formRetake Code (HIDDEN)This field is hidden when viewing the formQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/)This field is hidden when viewing the formCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
